EU Approval For Roche’s Pegasys Personalises Treatment For A Subgroup Of Hepatitis C Patients: Chance For Cure With Only 4 Months Of Treatment
Jun 30th 2008Drug InformationLiver Disease / Hepatitis
Roche announced that the European Commission has approved a shortened, 16-week course of treatment with Pegasys (peginterferon alfa-2a (40 KD)) plus Copegus (ribavirin) for certain hepatitis C patients.
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
